The company relies on sole source suppliers for raw materials, active pharmaceutical ingredients (APIs), finished drug product, and packaging for VYKAT XR. Disruptions from these suppliers due to pricing, availability, manufacturing or quality issues, payment disputes, or insolvency could adversely affect manufacturing and commercialization. Supply constraints may result in delays, increased costs, and product availability challenges, impacting operations and cash flows. Identifying alternative suppliers is uncertain, time-consuming, and costly, with qualification processes potentially requiring months or years. In the U.S., the company depends on a single specialty pharmacy for dispensing VYKAT XR, customer support, and related services, making sales highly dependent on the pharmacy's performance. Risks include ineffective dispensing, improper administration of copay programs, inaccurate inventory or patient data, delayed adverse event reporting, and insufficient resource allocation by the specialty pharmacy.
Soleno Therapeutics Inc's Comment on Supply Chain
The company relies on sole source suppliers for raw materials, active pharmaceutical ingredients (APIs), finished drug product, and packaging for VYKAT XR. Disruptions from these suppliers due to pricing, availability, manufacturing or quality issues, payment disputes, or insolvency could adversely affect manufacturing and commercialization. Supply constraints may result in delays, increased costs, and product availability challenges, impacting operations and cash flows. Identifying alternative suppliers is uncertain, time-consuming, and costly, with qualification processes potentially requiring months or years. In the U.S., the company depends on a single specialty pharmacy for dispensing VYKAT XR, customer support, and related services, making sales highly dependent on the pharmacy's performance. Risks include ineffective dispensing, improper administration of copay programs, inaccurate inventory or patient data, delayed adverse event reporting, and insufficient resource allocation by the specialty pharmacy.
Sources:
Soleno Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Soleno Therapeutics Inc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
